

Company Overview

Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women's intimate health company based in Englewood, Colorado. The company is focused on the commercialization of a revolutionary, non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The internationally patented Viveve® System incorporates clinically-proven, cryogen-cooled, monopolar radiofrequency (CMRF) energy to uniformly deliver deep-penetrating volumetric heat while gently cooling surface tissue to generate robust neocollagenesis in a single in-office session.

In the United States, the Viveve System is cleared by the Food and Drug Administration (FDA) for general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in over 50 countries. Consistent with these approvals, in the second quarter of 2018, Viveve initiated VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth following an Investigational Device Exemption (IDE) application approval from the FDA in March of 2018. Completion of the full 250 subject enrollment was announced in early March 2019. If successful, this trial could support a marketing application for a new U.S. commercial indication.

Viveve has fully enrolled LIBERATE-International, one of two planned independent, multicenter, randomized registration trials for the improvement of stress urinary incontinence in women and plans to re-submit an IDE to the FDA for LIBERATE-U.S. after conducting certain safety testing. The results of these two studies, if successful, could support marketing applications in the U.S and additional countries around the world for this new commercial indication.

Viveve Reports First Quarter 2019 Financial and Operating Results

May 9 2019, 4:02 PM EDT

Stock Overview

Symbol VIVE
Exchange Nasdaq
Market Cap 27.79m
Last Price \$0.59786
52-Week \$0.42 - \$4.34

05/17/2019 03:59 PM EDT

Investor Relations

Stern Investor Relations, Inc.
1270 Avenue of the Americas
Suite 408
New York, NY 10020
T: (212) 362-1200
Sarah@sternir.com

Management Team

Scott Durbin

Chief Executive Officer and Director

James Atkinson

Chief Business Officer and President

Suzon Lommel

Senior Vice President of Regulatory and Quality Affairs

Jim Maffezzoli

Senior Vice President of Global Marketing

Jim Robbins

Vice President of Finance and Administration
Principal Accounting and Financial Officer

Marty Kerber

Vice President of Operations

Sean Shapiro

Vice President of U.S. Sales

Lori McMillan

Vice President of Human Resources

Viveve Medical, Inc.

345 Inverness Drive South
Building B, Suite 250
Englewood, CO 80112

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.